

Introducing MRD**Vision**

See what others may miss

Whole-genome MRD detection with a one-in-a-million limit of detection:
Ultra-sensitive, panel-free monitoring



MRDVision**** is a whole-genome based, tumor-informed liquid biopsy platform designed to detect minimum residual disease (MRD) from circulating tumor DNA (ctDNA), at a low ppm level limit of detection (LOD).

Unlike existing MRD methods that rely on personalized panels, **MRD**Vision** scans and traces the whole genome** in every test, reducing the likelihood of missing mutations and recurrence.

Setting a new standard in MRD testing and precision oncology

Maximized signal

powered by the Inocras whole-genome platform

INOCRAS

Minimized noise

powered by **Ultima ppmSeq™**

 **ULTIMA GENOMICS**

Micro-level sensitivity

Detection threshold (LOD50): 1 ppm

95% limit of detection (LOD95): as low as 2 ppm
with >10,000 somatic mutations

Whole-genome insights every time

No panel required

Less fear of missing rare and complicated variants
Monitoring **WGS ctDNA longitudinally**

Available today, accessible at scale

RUO available today; CAP/CLIA in Jan. 2025

50% lower price vs. other existing MRD tests

2 week turnaround time



How MRD**Vision** works

WGS baseline:

Tumor-normal paired whole genome cancer profiling test for each patient

ctDNA monitoring:

Comparing WGS baseline vs. WGS data in ctDNA



What you'll get: Curated WGS cancer profiling data + WGS ctDNA for each MRD test

Unlock full potential in cancer research

Discover novel biomarkers and identify molecular subtypes in cancer

Exploring the therapeutic impact at a molecular level, detect resistance mechanisms, and monitor tumor evolution over time

Advance liquid biopsy research with ctDNA WGS to pioneer new approaches in non-invasive diagnostics, tracking genetic alterations with high sensitivity

Scale your research with our competitively priced MRD assay to expand your research capabilities – without compromising on precision or scope

Accelerate your clinical development

Stratify patients and discover novel patient subgroups for targeted therapies via whole-genome data and insights, driving more precise study design

Accelerate a clinical trial timeline using MRD as a surrogate marker to track early treatment response

Detect early signals on molecular changes to inform treatment success

We're here as your strategic research partner
Contact us at strategic_partnership@inocras.com